The ARHGAP32 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte line, providing a targeted loss-of-function model for ARHGAP32 via CRISPR/Cas9-mediated gene disruption. The polyclonal format maintains population-level genetic heterogeneity while ensuring robust ablation of the target gene, making it suitable for functional studies where clonal isolation is not required.
Jurkat cells are an immortalized human T-cell leukemia line originally isolated from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Widely utilized in immunology and oncology, these cells are ideal for investigating T-cell receptor (TCR) signaling, apoptosis, and HIV infection due to their well-characterized signaling pathways and ease of genetic manipulation.
ARHGAP32 encodes a Rho GTPase-activating protein (RhoGAP) that specifically accelerates the intrinsic GTP hydrolysis of Cdc42 and Rac1, thereby switching these molecular switches to their inactive GDP-bound states and suppressing actin polymerization. ARHGAP32 is activated by upstream signals including BDNF/TrkB, EphB receptors, and NMDA receptor-mediated calcium influx, and is phosphorylated by CaMKII. It forms signaling complexes with PSD-95 and Shank at excitatory synapses and with cortactin in dynamic actin structures. The ARHGAP32-Cdc42/Rac1 axis ultimately regulates the actin nucleation machinery, including the WAVE and Arp2/3 complexes, controlling lamellipodia and filopodia formation. Dysfunction of this pathway is implicated in neurodevelopmental disorders such as autism spectrum disorder and intellectual disability, and emerging evidence suggests roles in T-cell leukemia.
In the Jurkat T lymphocyte model, ARHGAP32 knockout disinhibits Cdc42 and Rac1, leading to enhanced actin polymerization and potentially altering key T-cell functions. The elevated GTPase activity is expected to promote actin-dependent processes such as cell migration, adhesion, and immune synapse formation. This polyclonal knockout cell population therefore provides a platform to investigate how sustained Rho GTPase signaling disrupts normal T-cell activation and signaling thresholds. Researchers can monitor downstream effectors like PAK kinase and the WAVE complex, and assess crosstalk with the PI3K/Akt pathway, which is frequently activated in T-cell acute lymphoblastic leukemia.
Typical applications include high-throughput screening for Rho GTPase inhibitors, biochemical assays for Cdc42/Rac1 activation via GST-pull-down or western blotting, fluorescence microscopy with phalloidin to visualize F-actin, and live-cell imaging of actin dynamics. Functional studies such as transwell migration assays and flow cytometric analysis of T-cell activation markers (e.g., CD69) can be conducted. These cells further enable investigation of ARHGAP32’s role in T-cell leukemia pathology and may serve as a model for cancer cell invasion. For further details or to inquire about this product, please contact Ascent Research.
